Jacob Stephen Thomas MD
Head & Neck Cancer
Assistant Clinical Professor of Medicine
Join to View Full Profile
1441 Eastlake AveLos Angeles, CA 90089
Phone+1 323-865-3105
Dr. Thomas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Jacob Thomas, MD, is an Oncologist based in Los Angeles, CA with an extensive background in medical education. He completed his fellowship in Medical Oncology at the University of Southern California and residency in Internal Medicine at UCLA David Geffen School of Medicine. He is also an alumnus of the University of Illinois College of Medicine. Dr. Thomas has contributed to several publications in his field, with the most recent focus on thyroid cancer among Hispanics and the efficacy of pembrolizumab in head-neck squamous cell carcinoma. He is actively involved in clinical trials, notably PRS-343 in combination with Atezolizumab in HER2-Positive Solid Tumors.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2015 - 2018
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2012 - 2015
University of Illinois College of MedicineClass of 2012
Certifications & Licensure
CA State Medical License 2014 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Start of enrollment: 2018 Aug 21
Publications & Presentations
PubMed
- First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors.Anthony El-Khoueiry, Omar Saavedra, Jacob Thomas, Claire Livings, Elena Garralda
Clinical Cancer Research. 2025-04-01 - Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles.Darin Poei, Sana Ali, Jacob S Thomas, Jorge J Nieva, Robert C Hsu
Cancer Research Communications. 2025-02-01 - Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis acr...Ryan Cooper, Dhruv Ramaswami, Jacob S Thomas, Jorge J Nieva, Robert Hsu
Discover Oncology. 2024-11-21
Press Mentions
Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingNovember 13th, 2021
Data from Intensity Therapeutics’ Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control, Abscopal Effects and Immune Response Activity in Patients with Advanced Solid TumorsNovember 7th, 2019
Hoag Hospital Clinical Investigator Discusses the Importance of Clinical Trials in the CommunityAugust 30th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
